Quote:
Originally Posted by Apia resurrected
Very promising isn't enough.
My company had studies on drugs where the first studies went really well even on humans.
Millions were invested and big studies established just to get a big disappointment in phase 3.
It went so far as that we thought a new drug would join the portfolio very soon, and than some months later came a big, big no.
https://www.reuters.com/article/us-n...-idUSKBN2B10HC
So am very cautious with my expectations. |
Key point - a NEW drug vs an in use druf for 4 plus decades. May not work great but does no harm (relative to other options).
And second point on adverse rate - mRNA studies of 40k participants. Ivermectin FDA studies then used in the wild with billions of doses administered so I feel plenty of data there to evaluate.